Because outcomes of patients who discontinue ibrutinib therapy are generally poor [12], next‐generation BTK inhibitors with more favourable tolerability profiles could provide an improved treatment option for patients with CLL who are unable to tolerate ibrutinib. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.